b"MyHEMENGS Cancer PanelsBackgroundHematologic diseases are characterized by aberrant geneinsertions/deletions and translocations under NCCN/ELN expression often resulting from specific genetic translocationsguidelines, as well as novel somatic variants that may have or mutations that lead to unregulated signal transduction.prognostic significance for hematologic diseases.These types of alterations allow classification of leukemias and lymphomas into specific subgroups and frequently suggestScreening with MyHEME allows for treatment decisions to be 1 made once all the relevant mutations are known, both in theTest Name information. Coupling comprehensive gene coverage treatment strategies. with enhanced depth of coverage, long read lengths, prevalent clones as well as the 'secondary' or 'tertiary' clones,MyHEME - NGS gene panel assayand the power of our robust annotation software and The MyHEME identifies clinically actionable, pathogenic, andwhich could become the new prominent clones leading tobioinformatics database, MyHEME identifies the underlying potentially pathogenic mutations in more than 700 uniquerecurrence.genes associated with hematological malignancies. UsingAssay Type somatic mutations that are present in as low as 5% allelic the latest version in Next-Generation Sequencing chemistry,frequency. The data and report include sequences of MyHEME identifies all somatic mutations, large and small Next-Generation Sequencing (NGS) mutations, which facilitates both minimal residual disease List of Genes on the MyHEME Panel: STAT6 STIL STK11 STK32A STK33 STK36 SUDS3 SUPT5H SUZ12 SYK SYNE1 TAF15For Research Use Only testing and temporal and longitudinal studies.TAL1 TAL2 TBL1XR1 TCF3 TCL1A TCL6 TERC TERT TET1 TET2 TFG TFPT TFRC TGDSA completed patient consent form must be submitted for DNA Targets (571 genes)TLR2 TLX1 TLX3 TMEM255B TNF TNFAIP3 TNFRSF14 TNFRSF17 TOP1 TP53 TP63 ABI1 ABL1 ABL2 ACSL6 ACVR1C ACVR2B ADGRG7 ADNP ADRBK1 AFF1 AFF3TPM3 TPM4 TPMT TRA2B TRAF3 TRIM24 TRIO TRIP11 TSC1 TSC2 TTBK1 TTL TYK2Method Description each sample sent to LabPMM.AFF4 AKAP13 AKT1 ALK ANKHD1 ANKRD26 ARAF ARHGAP26 ARHGEF12 ARID1ATYRO3 U2AF1 U2AF1L4 U2AF2 UBR5 VHL WAC WAPL WAS WEE1 WHSC1 WHSC1L1 ARID1B ARID2 ARID4B ARID5B ARNT ASXL1 ASXL2 ASXL3 ATG2B ATIC ATMWNK1 WNK3 WNK4 WT1 WWTR1 XPO1 XRCC1 ZBTB16 ZBTB33 ZBTB7B ZC3H18Using customized design, the coding and non-coding ATP2B3 ATR ATRX AXL B2M BAP1 BAX BAZ2A BCL10 BCL11A BCL11B BCL2 BCL3ZMYM2 ZMYM3 ZNF292 ZNF384 ZNF471 ZNF521 ZRSR2 exons of 571 genes are sequenced to an average depthIndications for TestingBCL6 BCL7A BCL9 BCOR BCORL1 BCR BIRC3 BLM BMI1 BRAF BRCA1 BRCA2of coverage of 1000x. Long reads enhance the ability to BRD4 BRIP1 BRPF1 BTG1 BTK BUB1 C15orf65 CACNA1E CALR CAMK1G CAMKK1RNA Targets and Gene Fusions (371 fusions)Stratifying patients with hematologic diseaseCAMTA1 CARD11 CARS CASC5 CBFA2T3 CBFB CBL CBLB CBLC CBX5 CBX7ABI1 ABL1 ABL2 ACER1 ACSL6 ADD3 ADGRG7 AFF1 AFF3 AFF4 AHI1 ALKidentify indels, including large internal tandem duplications CCDC6 CCND1 CCND2 CCND3 CD274 CD70 CD79A CD79B CDC42EP1 CDH23ANKRD28 AP2A2 ARHGAP20 ARHGAP26 ARHGEF12 ARHGEF17 ARNT ASXL1(ITDs). RNA sequencing of 371 genes identifies gene fusionsRecurrence of leukemia or lymphomaCDK11B CDK16 CDK6 CDKN1B CDKN2A CDKN2B CDKN2C CDX2 CEBPA CEBPEATF7IP ATIC AUTS2 BAALC BACH2 BAZ2A BCL10 BCL11A BCL11B BCL2 BCL2L1 CHD2 CHIC2 CIITA CLP1 CLTC CLTCL1 CNOT3 CPNE3 CREBBP CRLF2 CSF1RBCL3 BCL5 BCL6 BCL7A BCL9 BCOR BCR BIRC3 BRD1 BRWD3 BTBD18 BTG1and rearrangements, as well as provides gene expression CSF3R CSMD1 CSTF2T CTNNA1 CTNNB1 CUL1 CUX1 CXCR4 CYP1A1 DCLK1 DDR2C15orf65 CAPRIN1 CARS CASC5 CBFA2T3 CBFB CBL CCDC6 CCDC88C CCND1 DDX1 DDX10 DDX11 DDX23 DDX3X DDX41 DDX6 DEK DHX15 DHX29 DHX32CCND2 CCND3 CD274 CDK5RAP2 CDK6 CDX2 CEBPA CEBPB CEBPD CEBPE DICER1 DIS3 DNAJC11 DNM2 DNMT3A DNMT3B DOT1L DTX1 DUSP2 DYRK4CEP170B CEP85L CHD6 CHIC2 CHST15 CIITA CLCA2 CLP1 CLTC CLTCL1 CNTRL ECT2L EED EGFR EGR1 EGR2 EIF4A2 EIF4E2 ELF4 ELL ELN EP300 EPHA10 EPHA2CPSF6 CREBBP CRLF2 CUX1 DAB2IP DACH1 DACH2 DDX10 DDX6 DEK DMRT1 EPHA3 EPOR EPS15 ERBB2 ERBB3 ERG ESCO2 ETNK1 ETV3 ETV6 EWSR1 EZH2DTD1 DUSP22 EEFSEC EIF4A2 ELF4 ELL ELN EML1 ENAH EP300 EPOR EPS15TurnaroundShippingStorage EZR FAM175A FAM46C FANCA FANCC FANCD2 FANCE FANCF FANCG FASERC1 ERG ERVK-6 ERVW-1 ETS1 ETV6 EWSR1 FAM46C FCGR2B FCRL4 FEN1Interpretation Specimen RequirementsFAT3 FBXO11 FBXW7 FCGR2B FCRL4 FEV FGFR1 FGFR1OP FGFR2 FGFR3 FGFR4FGFR1 FGFR1OP FGFR1OP2 FGFR3 FIP1L1 FLT3 FNBP1 FOXO3 FOXO4 FOXP1Time Conditions ConditionsFH FHIT FIP1L1 FLI1 FLT1 FLT3 FNBP1 FOXO1 FOXO3 FOXO4 FOXP1 FSIP2 FSTL3FRA7H FRYL FSTL3 FUS GAPDH GAS5 GAS6 GAS7 GATA1 GIT2 GLIS2 GMPS FUBP1 FUS GAS6 GAS7 GATA1 GATA2 GATA3 GLI1 GMPS GNA13 GNAS GNB1GOLGA4 GOLGA6A GOT1 GPHN GPR34 GRHPR HIP1 HIPK1 HIST1H4I HLFAn interpretive10 to 14 DNA Ambient orRoom Temp GPHN GSKIP HDAC1 HDAC2 HDAC3 HFE HIP1 HIST1H1B HIST1H1E HIST1H3BHMGA2 HOXA10 HOXA11 HOXA13 HOXA9 HOXC11 HOXC13 HOXD11 HOXD13 HIST1H4I HLF HLX HNRNPK HOXA11 HOXA13 HOXA9 HOXC11 HOXC13 HOXD11HRASLS5 HSP90AA1 HSP90AB1 ID4 IGF2BP1 IGH IGK IGL IKZF1 IL2 IL21R IL3report will bebusiness daysCool; do notup to 72 HOXD13 HRAS HSP90AA1 HSP90AB1 ICE1 IDH1 IDH2 IKBKB IKZF1 IKZF2 IKZF3IQCG IRF4 IRS4 ITK JAK2 JAK3 KANK1 KAT6A KAT6B KDM5A KDSR KIAA15243 mL of peripheral blood in Heparin, issued indicatingfreeze hoursIKZF4 IL15 IL2 IL21R IL7R INPP5D INTS12 IRAK1 IRF1 IRF4 IRF8 ITK ITPKB JAK1 JAK2KIAA1549L KIF5B KMT2A KRAS KRT18P6 LASP1 LCK LCP1 LHX2 LHX4 LMBRD1EDTA or ACDJAK3 JMJD1C KAT6A KAT6B KDM2B KDM3B KDM5A KDM6A KDM8 KDR KDSRLMO1 LMO2 LNP1 LOC100289656 LPP LPXN LRMP LYL1 LYN MACROD1 MAFthe SNVs, indels,2-8 C upKIT KLHDC8B KLHL6 KMT2A KMT2B KMT2C KMT2D KRAS LASP1 LCK LCP1 LMO1MAFB MALT1 MAML2 MAP3K9 MAPRE1 MBNL1 MBTD1 MDS2 MECOMinversions and1 mL of bone marrow in Heparin, LMO2 LPP LRIG3 LRP1B LTB LUC7L2 LYL1 MAF MAFB MALT1 MAP2K1 MAP3K1MIR29A MKL1 MLF1 MLLT1 MLLT10 MLLT11 MLLT3 MLLT4 MLLT6 MN1 MNX1to 7 daysMAP3K13 MAPK1 MAU2 MDM2 MDM4 MDS2 MECOM MED1 MED12 MEF2BMSI2 MSN MTCP1 MUC1 MYB MYC MYH11 MYH9 MYO18A NACA NAPAtranslocationsEDTA or ACDMET METTL3 MIR142 MIR155 MKL1 MLF1 MLLT1 MLLT10 MLLT11 MLLT3 MLLT4NBEAP1 NCKIPSD NCOA2 NCOA3 NCOR1 NDE1 NEBL NF1 NFKB2 NID2 NINidentifiedMLLT6 MN1 MNX1 MPL MSI2 MSN MST1R MTA2 MTCP1 MTOR MUC1 MUTYHNIPBL NKX2-5 NOP2 NOTCH1 NPM1 NSD1 NTRK3 NUMA1 NUP214 NUP98 OLIG2Cell Pellets in cell culture MYB MYC MYD88 MYH11 MYH9 MYLK2 MYO3A NACA NBN NCKIPSD NCOA2P2RY8 PAFAH1B2 PAK1 PAX5 PBX1 PCM1 PCSK7 PDCD1LG2 PDE4DIP PDGFBmedia or buffered solutions without NF1 NF2 NFKB2 NFKBIE NIN NIPBL NKAP NLRP2 NOTCH1 NOTCH2 NPM1 NRASPDGFRA PDGFRB PER1 PHF21B PHF23 PICALM PIM1 PLAG1 PML POM121 NRG1 NRK NSD1 NT5C2 NUMA1 NUP214 NUP98 NXF1 OLIG2 P2RY8 PAFAH1B2POU2AF1 PPP1CB PRDM1 PRDM16 PRKAR1A PRKG2 PRRX1 PRRX2 PSIP1 PSMD2fixativesPAK1 PALB2 PAX5 PBRM1 PBX1 PCLO PCM1 PCSK7 PDCD1LG2 PDE4B PDE4DIPPTPRR PVT1 RABEP1 RALGDS RANBP17 RANBP2 RAP1GDS1 RARA RBM15 RCSD1 RHOA RHOH RMI2 RNF213 RNF217-AS1 RPL22 RPN1 RUNX1 RUNX1T1 SARNPPurified, high qualityPDGFB PDGFRA PDGFRB PDS5A PDS5B PEG3 PER1 PHF6 PICALM PIGA PIK3CA PIK3CD PIM1 PIP4K2A PLCG1 PLRG1 PML POLR2A POLR3B POT1 POU2AF1SART3 SEC31A SEPT2 SEPT5 SEPT6 SEPT9 SET SETBP1 SFPQ SH3D19 SH3GL1genomic DNAPOU2F2 PRDM1 PRDM16 PRDM9 PRF1 PRKCG PRKD3 PRPF3 PRPF8 PRRX1 PSIP1SLCO1B3 SNHG5 SNX29 SORBS2 SPECC1 SPTBN1 SQSTM1 SRSF3 SSBP2 PTCH1 PTEN PTPN11 PTPN14 PTPN2 PTPN5 PTPN6 PTPRC PTPRF PTPRT PYGLST6GAL1 STAT5B STIL STRN SYK TAF15 TAL1 TAL2 TAOK1 TCF3 TCL1A TCL6 TCTA RABEP1 RAD21 RALGDS RANBP17 RAP1GDS1 RARA RASA2 RBBP4 RBM15 RBMXTET1 TFG TFPT TFRC THADA TLX1 TLX3 TMEM255B TNFRSF17 TOP1 TP53BP1RNAREC8 REL RELN RET RHOA RHOH RMI2 RNF213 RNF217-AS1 ROBO1 RPL10 RPL22TP63 TPM3 TPM4 TRA TRAF1 TRB TRD TRIM24 TRIP11 TRPS1 TTL TYK2 USP16 RPL5 RPN1 RPS14 RPS15 RPS2 RPS6KA6 RPS6KB2 RUNX1 RUNX1T1 S1PR2 SAMHD1USP42 WHSC1 WHSC1L1 XBP1 YPEL5 YTHDF2 ZBTB16 ZFP64 ZFPM2 ZFYVE19 SAP130 SBDS SCML2 SEPT5 SEPT6 SEPT9 SET SETBP1 SETD1A SETD2 SETDB1ZMIZ1 ZMYM2 ZMYND11 ZNF384 ZNF521 ZNF687 PAXgene tube for BMA orSF3B1 SH2B3 SH2D1A SH3GL1 SKIV2L2 SMARCA2 SMARCA4 SMARCB1 SMC1APBMC with 5 mL minimum blood SMC3 SMC5 SMG1 SMO SNRNP200 SNX29 SNX7 SOCS1 SOS1 SP140 SPECC1volumeSPEN SPI1 SPOP SRP72 SRRM2 SRSF2 SRSF3 SRSF6 STAG1 STAG2 STAT3 STAT5B References1.Gabrilove JL et al. (2001) Hematologic Malignancies: An Opportunity for Targeted Drug Therapy. Oncologist 6 Suppl 5:1-3. 56 LabPMM Services Catalog 2020|57"